Publication | Open Access

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

Standard-dose PembrolizumabMedicineMelanomaClinical TrialsImmune Checkpoint InhibitorPharmacotherapyDermatologyCancer TreatmentImmunotherapyOncologyReduced-dose IpilimumabAdvanced Melanoma